By Canary Capital has filed a revised S-1 registration statement with the US Securities and Exchange Commission (SEC) for its proposed staked INJ exchange-traded fund (ETF).
The proposed ETF aims to combine the potential price appreciation of Injective (INJ) with the yield generated from staking the token, providing a unique avenue for investors seeking a more structured entry into the crypto market.
The proposed staked INJ ETF
The revised S-1 filing, which amends the earlier submission, details the structure and mechanics of the ETF.
If approved, the fund will list on the Cboe BZX Exchange, offering investors regulated exposure to INJ.
The trust will track the price of INJ using the INJ-USD CCIXber Reference Rate price index, which is calculated by CoinDesk Indices, ensuring a transparent and reliable benchmark for the token’s performance.
Investors will be able to participate in the ETF through creations and redemptions in blocks of 10,000 shares, allowing for institutional-grade liquidity and efficiency.
US Bancorp Fund Services has been appointed as the transfer agent and cash custodian, while BitGo Trust Company will serve as the custodian for INJ tokens.
The filing notes that all INJ tokens held by the trust will be staked through one or more staking providers, although the specific providers have not yet been disclosed.
The ETF’s staking program will allow investors to benefit from additional returns, but these rewards are subject to potential slashing and lock-up risks inherent to proof-of-stake networks.
Key operational details of the proposed ETF
The S-1 amendment reveals several operational details, including the price index, share distribution plan, and marketing agent, identified as Paralel Distributors LLC.
Despite these disclosures, certain critical information remains pending.
The ETF’s ticker symbol and management fee have not yet been specified, and these details are expected in future filings.
The sponsor, Canary Capital Group LLC, also emphasises that the ETF is not registered under the Investment Company Act of 1940, meaning it does not offer the same regulatory protections as traditional investment funds.
Investors should be aware that the shares are speculative and may fluctuate significantly in value.
Injective (INJ) price reaction
Contrary to most crypto ETF filings, the filing of the revised staked INJ ETF has had little impact on the price of Injective’s native token, which has been under immense bear pressure.
INJ price has depreciated by over 83% over the past year, with the last two weeks accounting for a 24% drop.
At press time, the altcoin traded at $4.56, down 5.5% in 24 hours and with recent activity showing a slight increase in trading volume and derivatives open interest on exchanges such as Binance and Bybit.
Technical indicators suggest the token is below key moving averages, while the Relative Strength Index (RSI), which is currently in the overbought region on the daily chart, hints at a potential rebound.
According to market analysts, if the cryptocurrency holds above $3.47 until a rebound occurs, it has the potential to recover above the first major resistance level at $5.25 in the next few days.
However, if the Injective’s price drops below $3.47, a further decline to the next support level at $1.57 is possible.
The post Canary Capital files revised S-1 for its proposed staked INJ ETF appeared first on Invezz
